On Monday, October 1, AACI will present two awards highlighting the importance of scientific discovery and philanthropic support in the cancer community.
Charles M. Perou, PhD, will receive AACI’s Distinguished Scientist Award in recognition of his accomplishments in the field of precision medicine and his groundbreaking research in characterizing the diversity of human tumors, which has profoundly impacted the treatment of patients with breast cancer.
The May Goldman Shaw Distinguished Professor of Molecular Oncology at UNC Lineberger Comprehensive Cancer Center, Dr. Perou is also the faculty director of UNC Lineberger’s Bioinformatics Group, co-director of its Breast Cancer Research Program, and a professor in its Genetics and Pathology & Laboratory Medicine departments.
Richard and Susan Rogel will be presented with the inaugural Champion for Cures Award in honor of their transformational philanthropy in support of cancer research and care.
AACI established the Champion for Cures Award to recognize individuals who demonstrate significant leadership in supporting efforts to cure cancer. Earlier this year, the Rogels pledged $150 million to the University of Michigan Comprehensive Cancer Center, which was renamed Rogel Cancer Center.
Their gift—the largest in the University of Michigan’s history—will fund endowed professorships, competitive research grants, and scholarships, and will help the cancer center establish a collaborative network that will bring international experts to campus for 6 to 12 months to develop innovative new projects.
“Donors are an integral part of the ecosystem of cancer care,” said AACI President Stanton L. Gerson, MD, director of Case Comprehensive Cancer Center. “AACI wanted to honor a family like the Rogels, who’ve demonstrated their commitment to the success of the cancer center through their investment in research.”
The award presentations are a highlight of the AACI/CCAF Annual Meeting, scheduled September 30 – October 2 in Chicago. The event convenes AACI cancer center directors and executive-level administrators with leaders of national cancer research and advocacy groups, industry, and government health agencies to develop solutions to common challenges and to share best practices.